<DOC>
	<DOCNO>NCT02807285</DOCNO>
	<brief_summary>The primary objective expand access program provide ocrelizumab treatment eligible participant primary progressive multiple sclerosis ( PPMS ) commercially available United States ( U.S. ) indication PPMS .</brief_summary>
	<brief_title>Expanded Access Program Ocrelizumab Participants With Primary Progressive Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Chronic Progressive</mesh_term>
	<criteria>Age 18 55 year ( inclusive ) Diagnosis PPMS accordance revise 2010 McDonald criterion presence document history cerebrospinal fluid oligoclonal band isoelectric focus elevate immunoglobulin G ( IgG ) index Expanded Disability Status Score ( EDSS ) 2.0 6.5 point screen For woman childbearing potential : agreement remain abstinent ( refrain heterosexual intercourse ) use contraceptive method result failure rate le ( &lt; ) 1 percent ( % ) per year treatment period least 24 week last dose study treatment Bcells replete , whichever long History relapsingremitting multiple sclerosis ( RRMS ) , progressive relapse multiple sclerosis ( PRMS ) secondary progressive multiple sclerosis ( SPMS ) screen History severe allergic anaphylactic reaction humanize murine monoclonal antibody History know presence recurrent chronic infection History recurrent aspiration pneumonia require antibiotic therapy History cancer , include solid tumor hematological malignancy ( except basal cell , situ squamous cell carcinoma skin , situ carcinoma cervix uterus excise resolve documented clean margin pathology ) History currently active primary secondary immunodeficiency History coagulation disorder ocrelizumab administer via infusion Known presence history neurologic disorder Significant , uncontrolled disease , cardiovascular ( include cardiac arrhythmia ) , pulmonary ( include chronic obstructive pulmonary disease ) , renal , hepatic , endocrine , gastrointestinal , significant disease Congestive heart failure Known active bacterial , viral , fungal , mycobacterial infection , infection Any concomitant disease may require chronic treatment systemic corticosteroid immunosuppressant course expand access program ( EAP ) Contraindications intolerance oral IV corticosteroid , include IV methylprednisolone Treatment therapies approve relapse form Multiple Sclerosis ( MS ) , include : Beta interferon , glatiramer acetate , fingolimod ( Gilenya® ) , teriflunomide ( Aubagio® ) , dimethyl fumarate ( Tecfidera® ) , IV immunoglobulin , plasmapheresis , immunomodulatory therapy within 12 week prior enrollment ( Participants exclude EAP due previous treatment rituximab ) Participants receive fingolimod ( Gilenya® ) dimethyl fumarate ( Tecfidera® ) lymphocyte count within normal value Previous treatment natalizumab ( Tysabri® ) within 6 month screen ( Participants eligible EAP treat natalizumab ( Tysabri ) 1 year ) Any previous treatment alemtuzumab ( Lemtrada® ) Any previous current treatment experimental procedure MS</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>